OTCMKTS:CCEL Cryo-Cell International - CCEL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cryo-Cell International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.03 -0.01 (-0.25%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.03▼$4.0850-Day Range$4.03▼$4.8952-Week Range$4.00▼$9.55Volume2,443 shsAverage Volume6,150 shsMarket Capitalization$34.34 millionP/E Ratio26.87Dividend YieldN/APrice Target$12.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort Interest Cryo-Cell International MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside197.8% Upside$12.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$167,193 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCryo-Cell International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Cryo-Cell International has a forecasted upside of 197.8% from its current price of $4.03.Amount of Analyst CoverageCryo-Cell International has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CCEL. Previous Next 0.0 Dividend Strength Dividend YieldCryo-Cell International does not currently pay a dividend.Dividend GrowthCryo-Cell International does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCEL. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Cryo-Cell International to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cryo-Cell International insiders have bought more of their company's stock than they have sold. Specifically, they have bought $167,193.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders33.80% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.18% of the stock of Cryo-Cell International is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cryo-Cell International is 26.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Cryo-Cell International is 26.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.07.Price to Book Value per Share RatioCryo-Cell International has a P/B Ratio of 8.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cryo-Cell International (OTCMKTS:CCEL) StockCryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.Read More Receive CCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter. Email Address CCEL Stock News HeadlinesNovember 16, 2022 | benzinga.comCryo-Cell International Chairman Trades Company's StockOctober 14, 2022 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2022 Financial ResultsFebruary 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.August 22, 2022 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Announces Special Cash DividendAugust 18, 2022 | seekingalpha.comCryo-Cell International to transfer listing from Nasdaq to NYSEJuly 15, 2022 | benzinga.comCryo-Cell International (NASDAQ:CCEL), Earnings Estimates, EPS, and RevenueJuly 15, 2022 | benzinga.comCryo-Cell International (NASDAQ:CCEL), Analyst Ratings, Price Targets, PredictionsJuly 11, 2022 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2022 Financial ResultsFebruary 2, 2023 | PressReach (Ad)Top AI Tech Stock To WatchToday's stock market news features a Robotics stock with blue sky potential.June 16, 2022 | bizjournals.comLogistics firm picks Garner for 240K-square-foot warehouseApril 15, 2022 | bizjournals.comWhy this German company is expanding in KnightdaleApril 13, 2022 | seekingalpha.comCRYO-CELL International GAAP EPS of $0.10, revenue of $7.26MApril 13, 2022 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2022 Financial ResultsMarch 23, 2022 | bizjournals.comStem cell firm launching Durham facility to attract businessMarch 18, 2022 | morningstar.comCord Blood Banking Leader Cryo-Cell Announces Extravault Biorepository Service | MorningstarMarch 16, 2022 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Announces Extravault Biorepository ServiceMarch 9, 2022 | finance.yahoo.comCryo-Cell Shares Its 2021 Annual Letter to ShareholdersFebruary 22, 2022 | seekingalpha.comCRYO-CELL International GAAP EPS of $0.00, revenue of $28.9MFebruary 22, 2022 | finance.yahoo.comCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2021January 15, 2022 | nasdaq.comCryo-Cell International, Inc. Common Stock (CCEL)December 20, 2021 | benzinga.comHow 2020's Hottest IPOs Have Performed In 2021October 27, 2021 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Announces Its Intent to Advance Clinical TrialsOctober 15, 2021 | benzinga.comCryo-Cell Reports Q3 2021 Revs $7.5MOctober 15, 2021 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2021 Financial ResultsSeptember 21, 2021 | nasdaq.comCryo-Cell International, Inc. Shares Near 52-Week Low - Market MoverSeptember 20, 2021 | finance.yahoo.comCryo-Cell International Announces Changes To Its Board of DirectorsSeptember 11, 2021 | bizjournals.comStem cell firm that partners with Duke University grabs space in DurhamSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter. Email Address CCEL Company Calendar Last Earnings10/15/2019Today2/02/2023Next Earnings (Estimated)2/20/2023Fiscal Year End11/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CCEL CUSIPN/A CIK862692 Webwww.cryo-cell.com Phone(813) 749-2100Fax813-855-4745Employees83Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+197.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.15 Trailing P/E Ratio26.87 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.08 million Net Margins4.34% Pretax Margin4.86% Return on Equity49.62% Return on Assets2.18% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.43 Sales & Book Value Annual Sales$28.89 million Price / Sales1.19 Cash Flow$0.41 per share Price / Cash Flow9.94 Book Value$0.49 per share Price / Book8.22Miscellaneous Outstanding Shares8,520,000Free Float5,640,000Market Cap$34.34 million OptionableNot Optionable Beta0.29 Key ExecutivesDavid I. PortnoyChairman & Co-Chief Executive OfficerMark L. PortnoyCo-Chief Executive Officer & DirectorJill M. TaymansChief Financial Officer & Vice President-FinanceOleg MikulinskyChief Information OfficerJoanne KurtzbergMedical DirectorKey CompetitorsGreenbrook TMSNASDAQ:GBNHLisata TherapeuticsNASDAQ:LSTAOntrakNASDAQ:OTRKCurative BiotechnologyOTCMKTS:CUBTBioRestorative TherapiesOTCMKTS:BRTXView All CompetitorsInsiders & InstitutionsDavid PortnoyBought 516 shares on 11/17/2022Total: $2,528.40 ($4.90/share)David PortnoyBought 10,000 shares on 11/14/2022Total: $48,000.00 ($4.80/share)David PortnoyBought 3,850 shares on 11/10/2022Total: $18,865.00 ($4.90/share)David PortnoyBought 20,000 shares on 11/8/2022Total: $97,800.00 ($4.89/share)View All Insider Transactions CCEL Stock - Frequently Asked Questions Should I buy or sell Cryo-Cell International stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cryo-Cell International in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CCEL shares. View CCEL analyst ratings or view top-rated stocks. What is Cryo-Cell International's stock price forecast for 2023? 1 analysts have issued 1-year price objectives for Cryo-Cell International's stock. Their CCEL share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 197.8% from the stock's current price. View analysts price targets for CCEL or view top-rated stocks among Wall Street analysts. How have CCEL shares performed in 2023? Cryo-Cell International's stock was trading at $4.23 at the beginning of the year. Since then, CCEL stock has decreased by 4.7% and is now trading at $4.03. View the best growth stocks for 2023 here. When is Cryo-Cell International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 20th 2023. View our CCEL earnings forecast. How were Cryo-Cell International's earnings last quarter? Cryo-Cell International, Inc. (OTCMKTS:CCEL) posted its quarterly earnings data on Tuesday, October, 15th. The company reported $0.13 earnings per share (EPS) for the quarter. The company earned $8.20 million during the quarter. Cryo-Cell International had a trailing twelve-month return on equity of 49.62% and a net margin of 4.34%. How often does Cryo-Cell International pay dividends? What is the dividend yield for Cryo-Cell International? Cryo-Cell International declared a dividend on Monday, August 22nd. Stockholders of record on Friday, September 2nd will be paid a dividend of $0.90 per share on Friday, September 9th. The ex-dividend date is Thursday, September 1st. Read our dividend analysis for CCEL. What other stocks do shareholders of Cryo-Cell International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cryo-Cell International investors own include NVIDIA (NVDA), Overstock.com (OSTK), Avid Technology (AVID), Boeing (BA), Enphase Energy (ENPH), OPKO Health (OPK), Riot Platforms (RIOT), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM) and Allena Pharmaceuticals (ALNA). What is Cryo-Cell International's stock symbol? Cryo-Cell International trades on the OTCMKTS under the ticker symbol "CCEL." How do I buy shares of Cryo-Cell International? Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cryo-Cell International's stock price today? One share of CCEL stock can currently be purchased for approximately $4.03. How much money does Cryo-Cell International make? Cryo-Cell International (OTCMKTS:CCEL) has a market capitalization of $34.34 million and generates $28.89 million in revenue each year. The company earns $2.08 million in net income (profit) each year or $0.15 on an earnings per share basis. How can I contact Cryo-Cell International? Cryo-Cell International's mailing address is 700 Brooker Creek Boulevard Suite 1800, Oldsmar FL, 34677. The official website for the company is www.cryo-cell.com. The company can be reached via phone at (813) 749-2100, via email at investors@cryo-cell.com, or via fax at 813-855-4745. This page (OTCMKTS:CCEL) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.